My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do.
Last year, Respira Technologies became Qnovia. It’s run by a former tobacco executive with vape experience, and it’s developing an inhaled nicotine platform for quitting smoking. On one hand, I found years ago that a pretty good platform for that is just to not inhale any more nicotine. But on the other hand, going from Q straight to N in a company name sounds clinically promising.
Source: finance.yahoo.com
Related posts:
JPMorgan Upgraded These Stocks Last Week — Should You Buy Now?
Nvidia will hit a $6 trillion valuation by the end of the year as investors start to realize how che...
Alibaba Stock Is Soaring. Brace for an Unprecedented Shakeup—and Spinoffs.
Fed rate hikes are over, economists say. Here's the impact on your money.
Nancy Pelosi Loads Up On More Nvidia Shares, Sells Part Of Microsoft Stake Before Q4 Earnings